---
title: "GPCR: Oral amylin and GLP-1 agonists show strong weight loss and safety in early and extension trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298317226.md"
description: "Positive clinical data show ACCG-2671 achieved 3.3% weight loss and strong target engagement in early trials, while aleniglipron delivered up to 16.2% weight loss at 72 weeks with favorable tolerability. Ongoing Phase 3 trials and additional studies are expected to further define their profiles.Original document: Structure Therapeutics Inc. [GPCR] Press release — Sep. 8 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-08T12:12:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298317226.md)
  - [en](https://longbridge.com/en/news/298317226.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298317226.md)
generator: "portal-rs"
---

# GPCR: Oral amylin and GLP-1 agonists show strong weight loss and safety in early and extension trials

Positive clinical data show ACCG-2671 achieved 3.3% weight loss and strong target engagement in early trials, while aleniglipron delivered up to 16.2% weight loss at 72 weeks with favorable tolerability. Ongoing Phase 3 trials and additional studies are expected to further define their profiles.

Original document: Structure Therapeutics Inc. \[GPCR\] Press release — Sep. 8 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [GPCR.US](https://longbridge.com/en/quote/GPCR.US.md)

## Related News & Research

- [Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin And Glp-1 Programs For Chronic Weight Management](https://longbridge.com/en/news/298316997.md)
- [Structure Therapeutics Announces Aleniglipron Trial Presentations at ObesityWeek 2026](https://longbridge.com/en/news/302325277.md)
- [Novo Nordisk's CagriSema delivers 21% weight loss at 68 weeks in obesity trial](https://longbridge.com/en/news/304224038.md)
- [Google responds to political backlash over removing search from schools that ban AI](https://longbridge.com/en/news/304182816.md)
- [Earnings to watch: Coherent (COHR) reports Q3 results tomorrow](https://longbridge.com/en/news/304045735.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**